Abeona Therapeutics INC Schedule 13G passive stakes

Nantahala Capital Management and its principals have reported a 9.99% beneficial ownership stake in Abeona Therapeutics Inc.

Nantahala Capital Partners Limited Partnership has filed a Schedule 13G reporting a 5.82% beneficial ownership stake in Abeona Therapeutics Inc.

AIGH Capital Management and affiliated entities now beneficially own over 5.4% of Abeona Therapeutics' common stock, as disclosed in a Schedule 13G filing.

Funicular Funds, LP, along with Cable Car Capital, LP and Jacob Ma-Weaver, has disclosed beneficial ownership of 3,007,329 shares, representing 5.3% of Abeona Therapeutics Inc.'s common stock.

Individual investor Daniel Kaufman has reported a 5.16% beneficial ownership stake in Abeona Therapeutics Inc., totaling 2,943,629 shares.

The Vanguard Group has reported a complete divestment of its beneficial ownership in Abeona Therapeutics Inc. common stock following an internal corporate realignment.

Adage Capital Management and its principals have fully divested their beneficial ownership in Abeona Therapeutics Inc., reporting a 0% stake.

Adage Capital Management, L.P. and its principals have disclosed a 9.99% beneficial ownership stake in Abeona Therapeutics Inc., including shares from warrants.

The Vanguard Group has reported a 5.07% beneficial ownership stake in Abeona Therapeutics Inc., holding 2,602,901 shares of common stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Abeona Therapeutics Inc.

Nantahala Capital Partners Limited Partnership has reported a passive beneficial ownership of 5.09% in Abeona Therapeutics Inc., totaling 2,618,462 common shares.

The James Russell Revocable Trust has disclosed a 5.3% beneficial ownership stake in Abeona Therapeutics Inc., holding 2,720,875 shares of Class A Common Stock.

Suvretta Capital Management, LLC, along with Aaron Cowen, reported a 5.2% beneficial ownership stake in Abeona Therapeutics Inc. common stock.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.8% beneficial ownership stake in Abeona Therapeutics Inc. as a passive investment.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a 9.99% beneficial ownership stake in Abeona Therapeutics Inc. as of March 31, 2025, held for investment purposes.

Adage Capital Management, L.P. and its principals, Robert Atchinson and Phillip Gross, have disclosed a beneficial ownership of 8.78% in Abeona Therapeutics Inc., totaling 4,411,572 shares, including warrants.

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, detailing their beneficial ownership of Abeona Therapeutics Inc. common stock as of March 31, 2025.